AKT1 and hepatocellular carcinoma: In this study, we report that an orally bioavailable PP2A activator SMAP has anti-HCC activity in vitro and in vivo through its ability to simultaneously inhibit PP2A substrates Akt and ERK activity, resulting in cell cycle arrest and ultimately cell death.